Streetbeat News

CMPGY

Compass Group Plc

http://www.compass-group.com/

CEO

Dominic Blakemore

Open

34.27

Mkt cap

58B

Volume

33K

High

34.48

P/E Ratio

42.00

52-wk high

36.33

Low

34.27

Div yield

0.02

52-wk low

26.55

FTI Consulting, Inc. announced that Dr. Ali Hortaçsu, a distinguished professor of economics, has affiliated with its subsidiary Compass Lexecon.

Portfolio Pulse from

March 14, 2025 | 11:45 am

Compass is reportedly considering acquiring Berkshire Hathaway's real estate brokerage business, according to a report by the Wall Street Journal.

Portfolio Pulse from

March 14, 2025 | 11:15 am

Compass (COMP) has been identified as a stock with strong recent momentum while still being reasonably priced, making it an attractive option for investors seeking value and growth.

Portfolio Pulse from

March 12, 2025 | 2:00 pm

FTI Consulting, Inc. has announced that Dr. William Rogerson, an expert in antitrust and economics, has joined its subsidiary Compass Lexecon.

Portfolio Pulse from

March 12, 2025 | 11:45 am

FTI Consulting, Inc. has appointed Dr. Mary T. Coleman as the Head of the U.S. Antitrust practice at its Compass Lexecon subsidiary.

Portfolio Pulse from

March 10, 2025 | 11:45 am

Compass Diversified's Series C preferred shares offer an 8.3% yield and trade at a 5% discount to par value. The company's strong Q4 2024 results, with 14% YoY sales growth and 25% adjusted EBITDA growth, support a positive outlook, making these shares appealing in a volatile market.

Portfolio Pulse from

March 05, 2025 | 1:15 pm

FTI Consulting, Inc. has announced the appointment of healthcare economist Matthew Grennan to its subsidiary, Compass Lexecon, as part of its ongoing investment in the firm.

Portfolio Pulse from

March 05, 2025 | 12:45 pm

Compass Lexecon, a subsidiary of FTI Consulting, has expanded its presence in Italy by opening a new office in Rome. This move aims to enhance client service capabilities across the nation.

Portfolio Pulse from

March 04, 2025 | 8:45 am

FTI Consulting, Inc. announced that health economist Jonathan Kolstad has affiliated with its subsidiary Compass Lexecon.

Portfolio Pulse from

March 03, 2025 | 12:45 pm

Compass Pathways is leveraging regulatory support and promising clinical data in the psychedelic biotech sector. Despite skepticism and high cash burn, it has $165.1 million in cash reserves, providing 4-6 quarters of runway. COMP360 shows promise for treatment-resistant depression and PTSD.

Portfolio Pulse from

February 28, 2025 | 10:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.